2019
DOI: 10.1111/bph.14783
|View full text |Cite
|
Sign up to set email alerts
|

Tipping the scales: Are females more at risk for obesity‐ and high‐fat diet‐induced hypertension and vascular dysfunction?

Abstract: Obesity is a common metabolic disorder that has become a widespread epidemic in several countries. Sex and gender disparities in the prevalence of cardiovascular disease (CVD) have been well documented with premenopausal women having a lower incidence of CVD than age-matched men. However, women are more likely than men to suffer from obesity, which can predispose them to a greater risk of CVD. The mechanisms underlying high-fat diet (HFD)-or obesity-induced hypertension are not well defined, although immune sy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
8
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 134 publications
(166 reference statements)
1
8
0
Order By: Relevance
“…In particular, the growth of sex/gender research in pharmacology has stimulated the commissioning of a BJP Themed Issue on this topic in 2019. In this themed issue alone, there are reviews and original articles demonstrating that sex is an important determinant of physiology, disease phenotype, and drug response from diverse systems of the body spanning across schizophrenia (Gogos, Ney, Seymour, Van Rheenen, & Felmingham, 2019), fear sensation (Clark et al, 2019) to metabolism (Henstridge, Abildgaard, Lindegaard, & Febbraio, 2019) and obesity (Taylor, Ramirez, Musail, & Sullivan, 2019). A focus upon sex driving diversity in drug response is also evident from the literature: Recent examples include that airway smooth muscle, isolated from obese females, manifests greater agonist‐induced excitation–contraction coupling than those derived from lean males, females, or from obese males (Orfanos et al, 2018) and that sex differences in the thermoregulatory and behavioural responses to the CNS stimulant, cathinone (Alsufyani & Docherty, 2017), have been identified.…”
Section: Evidence For Sex Differences That Affect Pharmacologymentioning
confidence: 99%
“…In particular, the growth of sex/gender research in pharmacology has stimulated the commissioning of a BJP Themed Issue on this topic in 2019. In this themed issue alone, there are reviews and original articles demonstrating that sex is an important determinant of physiology, disease phenotype, and drug response from diverse systems of the body spanning across schizophrenia (Gogos, Ney, Seymour, Van Rheenen, & Felmingham, 2019), fear sensation (Clark et al, 2019) to metabolism (Henstridge, Abildgaard, Lindegaard, & Febbraio, 2019) and obesity (Taylor, Ramirez, Musail, & Sullivan, 2019). A focus upon sex driving diversity in drug response is also evident from the literature: Recent examples include that airway smooth muscle, isolated from obese females, manifests greater agonist‐induced excitation–contraction coupling than those derived from lean males, females, or from obese males (Orfanos et al, 2018) and that sex differences in the thermoregulatory and behavioural responses to the CNS stimulant, cathinone (Alsufyani & Docherty, 2017), have been identified.…”
Section: Evidence For Sex Differences That Affect Pharmacologymentioning
confidence: 99%
“…The study also found that most of the respondents with hypertension were women. 10 The characteristics of respondents based on education are mostly elementary schools. The level of education is one of the factors affecting knowledge.…”
Section: Methodsmentioning
confidence: 99%
“…ED is a hallmark of obesity-induced hypertension. Insulin resistance and increased systolic blood pressure led to ED in obesity; however, targeting these factors presented with different benefits depending on sex ( 61 ) and ethnic group ( 62 ). RAS hyperactivity was often thought to result from Ang II-dependent stimulation of the Ang II type 1 receptor (AT1R).…”
Section: Targeting At-ec Axis To Treat Obesity-induced Ed/cvdmentioning
confidence: 99%